Kwality Pharmaceuticals Limited

Equities

KPL6

INE552U01010

Pharmaceuticals

Market Closed - Bombay S.E. 06:19:01 2024-04-26 am EDT 5-day change 1st Jan Change
507 INR +1.36% Intraday chart for Kwality Pharmaceuticals Limited +13.03% +26.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kwality Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Kwality Pharmaceuticals Limited Provides Update on Resumption of Operations At Amritsar CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Kwality Pharmaceuticals Discloses Completion of EU GMP Inspection at Himachal Pradesh, India Unit MT
Kwality Pharmaceuticals Limited Receives ANVISA Approval for Cephalosporin Plant (Unit -II) CI
Kwality Pharmaceuticals Limited Announces Change in Directorate CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bulgarian Drug Agency to Conduct Audit on Kwality Pharmaceuticals' Plant in Himachal Pradesh, India MT
Kwality Pharmaceuticals to Bring Oncology Injection in Brazil MT
Kwality Pharmaceuticals to Market Oncology Injection in Brazil MT
Kwality Pharmaceuticals Received ANVISA Approval For Oncology Injection CI
Kwality Pharmaceuticals Receives ANVISA Approval For Oncology Injection CI
Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
ICRA Assigns BBB Rating on Kwality Pharmaceuticals' Bank Loans; Outlook Stable MT
Kwality Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Kwality Pharmaceuticals Gets In-Principle Approval to Migrate to BSE Main Board MT
Kwality Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023 CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2021 CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2021 CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2020 CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2020 CI
Kwality Pharmaceuticals Limited Resumes Operations of its All the Units & Plants in India CI
Chart Kwality Pharmaceuticals Limited
More charts
Kwality Pharmaceuticals Limited is a manufacturer of finished pharmaceutical formulations in a dosage form. The Company is engaged in the business of manufacturers, buyers, and sellers of and dealers in all kinds of drug intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages, and other medical preparations. It manufactures exports pharmaceutical formulations in liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments, external preparations, oral rehydration solutions (ORS), and others in various categories like beta lactam and non-beta lactam, hormones, cytotoxic (oncology) and effervescent. The Company specializes in handling customized business as per the requirements. The Company has about 48 different sections available at their production centers. The Company has registered its products in different countries of Europe, Africa, Asia, and others.
More about the company
  1. Stock Market
  2. Equities
  3. KPL6 Stock
  4. News Kwality Pharmaceuticals Limited
  5. Kwality Pharmaceuticals to Market Oncology Injection in Brazil